US 10,376,600 B2
Early disease detection and therapy
Gholam A. Peyman, Sun City, AZ (US)
Filed by Gholam A. Peyman, Sun City, AZ (US)
Filed on Mar. 18, 2016, as Appl. No. 15/73,845.
Claims priority of provisional application 62/303,219, filed on Mar. 3, 2016.
Prior Publication US 2017/0252466 A1, Sep. 7, 2017
Int. Cl. A61K 49/22 (2006.01); A61K 47/69 (2017.01); A61K 47/68 (2017.01); A61K 41/00 (2006.01); A61K 49/00 (2006.01); A61K 45/06 (2006.01)
CPC A61K 49/221 (2013.01) [A61K 41/0028 (2013.01); A61K 41/0057 (2013.01); A61K 45/06 (2013.01); A61K 47/68 (2017.08); A61K 47/6923 (2017.08); A61K 47/6929 (2017.08); A61K 49/0058 (2013.01); A61K 49/0067 (2013.01); A61K 49/225 (2013.01)] 22 Claims
 
1. A method for early stage detection and treatment of a pathology in a patient, the method comprising the following steps:
administering a pathology-specific antibody-coated nanoparticle into a patient's circulation, the pathology-specific antibody-coated nanoparticle comprising a nanoparticle bound to a pathology-specific antibody and further conjugated with an immune checkpoint inhibitor in the form of a monoclonal antibody, wherein the pathology-specific antibody and monoclonal antibody are different,
allowing a time interval for the pathology-specific antibody of the antibody-coated nanoparticle to attach to a specific antigen in a circulating vesicle or cell,
thereafter exciting the antibody-coated nanoparticle with an energy source in a retinal vessel in the patient to elicit a nanoparticle-specific wavelength of light response from the antibody-coated nanoparticle attached to the circulating vesicle or cell indicating an early stage pathology in the patient due to the presence of the specific antigen to which the pathology-specific antibody of the antibody-coated nanoparticle is bound,
imaging and quantifying the nanoparticle-specific wavelength of light response in the retinal vessel in the patient for detection of the early stage pathology prior to a mass associated with the early stage pathology growing beyond a diameter of 3-4 mm and causing a clinical symptom, and
treating the pathology using the monoclonal antibody so as to facilitate leukocyte mediated destruction, wherein the pathology is cancer.